Interpace Biosciences, Inc.
IDXG
$1.25
$0.00280.23%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 308.47% | 1,078.29% | 33.33% | 156.91% | 95.68% |
| Total Depreciation and Amortization | -46.31% | -66.78% | -67.81% | -50.08% | -44.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -100.00% | 0.00% |
| Total Other Non-Cash Items | 13.30% | -98.07% | -37.11% | -70.46% | -96.65% |
| Change in Net Operating Assets | -83.32% | -20.65% | -1,149.35% | 44.30% | 133.89% |
| Cash from Operations | 91.49% | 241.61% | -105.12% | 513.04% | 134.06% |
| Capital Expenditure | -243.42% | -77.48% | 56.92% | 27.55% | -280.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 100.00% | -93.27% |
| Cash from Investing | -250.00% | 13.60% | 56.92% | 87.08% | -95.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -185.71% | -100.00% | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | 70.37% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00% | -185.71% | -100.00% | -2,288.68% | -3,291.49% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 300.00% | -53.38% | -189.32% | -3.58% | -101.12% |
